Clinical trial
Antiproteinuric Effect of Valsartan and Lisinopril
NCT00171574 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00171574 |
|---|---|
| Title | Antiproteinuric Effect of Valsartan and Lisinopril |
| Official title | Antiproteinuric Effect of Valsartan, Lisinopril and Valsartan Plus Lisinopril in Non-diabetic and Diabetic Renal Disease: a Randomized, Double Blind, Parallel Group, Controlled Trial With 5 Months Follow-up |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hypertension, Diabetic Nephropathy |
| Intervention type | Drug |
| Interventions | Valsartan, Valsartan plus HCTZ, Lisinopril |
| Enrollment | 124 |
| Start date | Nov 1, 2004 |
| Primary completion | Jul 1, 2006 |
| Completion | Jul 1, 2006 |
| First posted | Sep 15, 2005 |
| Last update posted | Feb 24, 2017 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: